Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HMGCR | P04035 | 2/20 | 0.56 |
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | PAM | P19021 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472097 | 1.00 | RECQL (0.60) | RECQLTDP1PTPN7MAPTALDH1A1 | |
| SCHEMBL31264376 | 0.95 | PTPN7 (0.64) | RECQLTDP1PTPN7MAPTALDH1A1 | |
| SCHEMBL14450970 | 0.91 | PTPN7 (0.56) | RECQLTDP1PTPN7MAPTALDH1A1 | |
| SCHEMBL15469155 | 0.87 | PTPN7 (0.53) | RECQLTDP1PTPN7MAPTALDH1A1 | |
| SCHEMBL851539 | 0.84 | CYP1A2 (0.53) | RECQLTDP1PTPN7MAPTALDH1A1 | |
| SCHEMBL116995 | 0.84 | DGKA (0.75) | TDP1MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL454 | 0.84 | DGKA (0.75) | TDP1MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL2309907 | 0.84 | DGKA (0.68) | TDP1MAPTALDH1A1KDM4EMEN1 | |
| Hexane SCHEMBL2349171 | 0.84 | DGKA (0.75) | TDP1MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL8375548 | 0.84 | DGKA (0.75) | TDP1MAPTALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140147428-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140050712-A1 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140044692-A1 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | RECQL 2845/4885TDP1 2225/4885PTPN7 4307/4885 |
| US-20140147428-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | RECQL 3923/4885TDP1 634/4885PTPN7 4832/4885 |
| US-20140050712-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | RECQL 3228/4885TDP1 3724/4885PTPN7 2783/4885 |
| US-20140044692-A1 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | NDUFAB1, PC, HADHB | RECQL 978/4885TDP1 1546/4885PTPN7 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.